Immunisation Programmes and Vaccine-Preventable Conditions – Routine Schedules

Definition and Core Concept

This article defines Immunisation (vaccination) as the process by which a person is made resistant to a specific infectious condition, typically through administration of a vaccine that stimulates the body’s own immune system to produce protective antibodies and memory cells. Vaccine-preventable conditions are those for which effective vaccines exist, reducing or eliminating the occurrence of infection, disease, and transmission. Core features of immunisation programmes: (1) routine childhood immunisation schedules (recommended vaccines by age, typically birth through adolescence), (2) adults and catch-up vaccination (tetanus, diphtheria, pertussis, influenza, pneumococcal, herpes zoster, human papillomavirus – HPV, hepatitis B), (3) maternal immunisation (influenza, pertussis during pregnancy to protect newborn), (4) travel and occupational vaccines (yellow fever, typhoid, hepatitis A, rabies, meningococcal), (5) mass vaccination campaigns (supplementary immunisation activities for outbreak control or elimination goals). The article addresses: stated objectives of immunisation programmes; key concepts including herd immunity, vaccine efficacy and effectiveness, primary series, and booster doses; core mechanisms such as cold chain management, immunisation registries, and vaccine safety monitoring; international comparisons and debated issues (vaccine hesitancy factors, mandatory vaccination policies, global access equity); summary and emerging trends (mRNA vaccine platforms, combination vaccines, needle-free delivery); and a Q&A section.

1. Specific Aims of This Article

This article describes immunisation programmes without endorsing specific vaccines or policies. Objectives commonly cited: reducing morbidity and mortality from vaccine-preventable conditions, achieving and maintaining elimination or eradication targets (polio, measles, rubella, tetanus), reducing healthcare costs associated with outbreaks, and protecting vulnerable individuals who cannot be vaccinated (infants, pregnant individuals, immunocompromised persons, those with medical contraindications). The article notes that immunisation prevents an estimated 4-5 million deaths annually worldwide, yet approximately 20-25 million children remain under-vaccinated or unvaccinated each year.

2. Foundational Conceptual Explanations

Key terminology:

• Herd immunity (population immunity): Protection conferred to unvaccinated individuals when a sufficiently high proportion of the population is immune (through vaccination or prior infection), reducing transmission. Threshold = 1 – 1/R₀. For highly transmissible conditions (measles, R₀ 12-18), herd immunity threshold is 90-95% coverage.
• Vaccine efficacy (VE): Relative risk reduction in a controlled clinical trial (e.g., 95% efficacy means vaccinated group has 95% fewer cases than unvaccinated group under ideal conditions).
• Vaccine effectiveness (VE – observational): Performance in real-world settings, often slightly lower than efficacy due to variations in storage, administration, population characteristics.
• Primary series: Initial doses required for protection (e.g., diphtheria-tetanus-pertussis – DTaP: 3 doses in infancy; measles-mumps-rubella – MMR: 2 doses).
• Booster dose: Additional dose given after primary series to extend or restore protection (e.g., tetanus booster every 10 years).
• Cold chain: Temperature-controlled supply chain (2-8°C for most vaccines; some require -20°C or -70°C – mRNA vaccines) from manufacturer to administration point. Breaks reduce vaccine potency.

Global vaccine coverage (WHO/UNICEF estimates, 2023):

• Third dose of diphtheria-tetanus-pertussis (DTP3) – global coverage: 81% (range 50-99%).
• Measles first dose (MCV1): 83%.
• Measles second dose (MCV2): 71%.
• Fully vaccinated (all recommended antigens by age 2): 60-70% globally.

Vaccine-preventable conditions examples (avoiding prohibited terms):

• Measles: Highly contagious, causes fever, rash, complications (pneumonia, brain inflammation). Elimination requires >95% coverage.
• Poliomyelitis (polio): Paralytic disease; eradicated from most regions (endemic in two countries as of 2024).
• Pertussis (whooping cough): Severe in infants (<6 months) leading to breathing difficulty and hospitalisation.
• Diphtheria: Respiratory or cutaneous infection, causes airway obstruction and heart damage.
• Tetanus: Bacterial toxin causing muscle rigidity; vaccine prevents, no herd immunity (spores in soil, not transmitted person-to-person).
• Rubella: Mild in children; in pregnancy causes congenital rubella syndrome (multiple birth defects).
• Hepatitis B: Liver infection; chronic infection leads to cirrhosis and liver cancer. Vaccine prevents transmission from mother to newborn and horizontal spread.
• Influenza (flu): Seasonal epidemics; vaccine reduces severe illness and hospitalisation (effectiveness 40-60% depending on strain match).
• Pneumococcal (pneumonia, meningitis, bloodstream infections): Two vaccine types (conjugate – PCV13/15/20, polysaccharide – PPSV23).
• Varicella (chickenpox): vaccine prevents primary infection and reduces risk of later shingles (herpes zoster).

3. Core Mechanisms and In-Depth Elaboration

Routine childhood immunisation schedule (US CDC, 2025 – example; varies by country):

• Birth: Hepatitis B (HepB) – first dose.
• 2 months: HepB (second), DTaP, Haemophilus influenzae type b (Hib), pneumococcal conjugate (PCV13), inactivated poliovirus (IPV), rotavirus (RV).
• 4 months: DTaP, Hib, PCV13, IPV, RV (second doses).
• 6 months: HepB (third), DTaP (third), PCV13 (third), IPV (third – optional), RV (third – depending on brand).
• 12-15 months: MMR, Varicella (chickenpox), Hib (fourth), PCV13 (fourth), HepA (hepatitis A).
• 4-6 years (pre-school): DTaP (fifth), IPV (fourth), MMR (second), Varicella (second).
• 11-12 years: Tdap (tetanus, diphtheria, pertussis booster), HPV (2 or 3 doses), meningococcal ACWY.
• 16-18 years: Meningococcal B (optional/selectively recommended), second meningococcal ACWY.

Adults vaccines (selected):

• Influenza: annually, all adults.
• Td or Tdap: every 10 years.
• Pneumococcal (PPSV23): age 65+ (or younger with certain conditions).
• Zoster (shingles) – recombinant (RZV) age 50+ (or immunocompromised younger).
• RSV (respiratory syncytial virus) for older adults (60+) and pregnant individuals.

Maternal vaccination:

• Tdap in each pregnancy (optimal 27-36 weeks) to pass pertussis antibodies to newborn.
• Influenza vaccine in any trimester.
• RSV vaccine during pregnancy (32-36 weeks) to protect infant.

Cold chain management (WHO):

• Storage: refrigerators dedicated to vaccines (no food/beverages), temperature logs (twice daily), alarm systems.
• Transport: vaccine carriers and cool boxes with conditioned ice packs (not frozen if vaccine requires 2-8°C).
• Freeze-sensitive vaccines (DTaP, HepB, Hib, IPV, pneumococcal) damaged if frozen.
• Heat-sensitive vaccines (MMR, varicella, zoster) reconstituted immediately before use.

Immunisation information systems (IIS – electronic registries):

• Track doses administered, patient demographics, due dates, coverage rates.
• Facilitate reminder/recall systems (postcards, phone calls, text messages).
• Provide data for school entry compliance.

Vaccine safety monitoring systems:

• Passive surveillance (voluntary reporting): Vaccine Adverse Event Reporting System (VAERS, US), EudraVigilance (EU), Yellow Card (UK). Detects rare adverse events; cannot determine causality.
• Active surveillance (VSD – Vaccine Safety Datalink, US): Real-time analysis of electronic health record data from large populations; can estimate risk of specific outcomes (e.g., seizure after MMR).
• Global Vaccine Safety Initiative (WHO): Multi-country collaboration.

Effectiveness evidence (real-world impact):

• Measles: Before vaccine (pre-1963), 2-3 million deaths annually. After widespread vaccination, deaths reduced >95% (elimination in many regions). Outbreaks occur when coverage falls below 90-95%.
• Polio: Global cases reduced from 350,000 (1988) to <100 (2023). Two countries remain endemic.
• Pertussis: Infant hospitalisations reduced >90% in countries with high booster coverage.
• Influenza vaccination in older adults: Reduces hospitalisation by 30-50% and mortality by 40-60% (observational studies, season-dependent).
• HPV vaccination: Countries with high coverage (e.g., Australia, Sweden) show 80-90% reduction in genital warts (within 5-10 years) and 50-70% reduction in high-grade cervical lesions.

4. Comprehensive Overview and Objective Discussion

International vaccine coverage (DTP3, measles first dose – WHO 2023 estimates):

Debated issues:

1. Vaccine hesitancy factors: WHO lists as top global health challenge (2019). Drivers: complacency (low perceived risk), convenience (access barriers), confidence (trust in vaccine safety, providers, system). Interventions: provider communication training (motivational interviewing), reminder systems, school mandates, social norm messaging.
2. Mandatory vaccination policies for school entry: Many jurisdictions require certain vaccines for school attendance (US states, Australia, Italy, France). Evidence shows mandates increase coverage (by 5-15 percentage points) but may provoke backlash. Philosophical and religious exemptions vary.
3. Global vaccine access and equity (COVAX, Gavi): Low- and middle-income countries have lower coverage (60-80% vs 90-95% in high-income). Gavi (Vaccine Alliance) subsidises vaccines for 70+ countries; has immunised >1 billion children. Supply chain, cold chain, health worker shortages persist.
4. Risk communication during vaccine safety events: Rare but serious adverse events (e.g., intussusception with rotavirus vaccine, allergic reactions) occur. Transparent communication of absolute risk, comparison to benefits, and alternative options is recommended. Overly cautious regulatory responses may reduce public confidence.

5. Summary and Future Trajectories

Summary: Immunisation programmes prevent 4-5 million deaths annually. Routine schedules include childhood, adolescent, adults, and maternal vaccines. Cold chain and immunisation registries are essential for programme success. Vaccine safety is monitored through passive and active surveillance. Global coverage (81% DTP3) remains below elimination targets for some conditions. Vaccine hesitancy and access inequities are ongoing challenges.

Emerging trends:

• mRNA vaccine platforms (rapid development, high efficacy, scalable production): Success for COVID-19; now being applied to influenza, RSV, cytomegalovirus, and cancer vaccines. Cold chain requirements (-70°C) remain challenging for low-resource settings.
• Combination vaccines (reducing number of injections): Hexavalent (DTaP-HepB-Hib-IPV) widely used; pentavalent and hexavalent reduced injection pain and improved coverage.
• Needle-free delivery systems (jet injectors, microarray patches, intranasal, oral vaccines): Patches under trial for measles-rubella, influenza. Could reduce need for trained injectors and cold chain (some patches stable at room temperature for months).
• Vaccine confidence monitoring (BeSD – Behavioural and Social Drivers of Vaccination): Standardised surveys to identify barriers and tailor interventions at local level.

6. Question-and-Answer Session

Q1: How are vaccine safety and efficacy measured before approval?
A: Phase I (small group, safety, dosing). Phase II (hundreds, immunogenicity, dose confirmation). Phase III (thousands, randomised controlled trial for efficacy and rare safety events). Licensure requires demonstrating efficacy and acceptable safety profile. Phase IV (post-licensure) continues safety monitoring in larger populations.

Q2: What is the difference between inactivated and live-attenuated vaccines?
A: Inactivated (killed) vaccines (polio, influenza, hepatitis A) contain non-replicating antigen; require multiple doses and boosters; cannot cause disease even in immunocompromised individuals. Live-attenuated (weakened) vaccines (MMR, varicella, rotavirus, yellow fever) produce stronger, longer-lasting immunity; generally contraindicated in severely immunocompromised persons.

Q3: Can vaccines cause the condition they are designed to prevent?
A: For inactivated vaccines, no – they contain killed pathogen. For live-attenuated vaccines, extremely rare cases of vaccine-strain disease occur in severely immunocompromised individuals (e.g., vaccine-strain polio, disseminated BCG). MMR vaccine does not cause autism or inflammatory bowel disease – multiple large studies (n>1 million) have found no association.

Q4: Why are some vaccines recommended during pregnancy?
A: Influenza (any trimester) – pregnant individuals have higher risk of severe illness. Tdap (27-36 weeks) – passes pertussis antibodies to newborn, protecting infant during first months before they can be vaccinated. RSV vaccine (32-36 weeks) – similarly protects newborn from severe RSV illness.

https://www.who.int/immunization/
https://www.cdc.gov/vaccines/
https://www.gavi.org/
https://www.ecdc.europa.eu/en/immunisation-vaccines